Welcome to our dedicated page for Establishment Labs Holdings news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Holdings stock.
Establishment Labs Holdings Inc. (ESTA) is a leading global medical technology company, renowned for its innovation in the field of medical devices and aesthetics. Specializing in advanced silicone-filled breast and body shaping implants, the company has over 30 years of experience in breast implant manufacturing. Establishment Labs designs, develops, manufactures, and markets an extensive product portfolio that ensures safety and meets the current needs and preferences of plastic surgeons and patients.
Known for its flagship product, Motiva Implants®, Establishment Labs has set a benchmark in the industry for product innovation and safety. The company operates in multiple geographical segments, including Europe, Latin America, Asia-Pacific/Middle East, and other regions. Establishment Labs' products are distributed to medical distributors, physicians, hospitals, and clinics through direct sales channels.
Recent achievements include the continued global expansion of the Motiva Implants® brand and strategic partnerships aimed at advancing medical and aesthetic technology. With a strong focus on the future, the company is dedicated to pushing the boundaries of innovation and safety in medical devices.
Establishment Labs maintains a robust financial condition, driven by its commitment to quality and continuous improvement. The company’s ongoing projects include research and development initiatives aimed at introducing new and improved products that align with market demands.
For the latest updates and relevant information about Establishment Labs Holdings Inc., stay tuned to this page for the most recent news and developments.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced participation in the UBS Global Healthcare Virtual Conference, taking place from May 24-26, 2021. CEO Juan José Chacón-Quirós and CFO Renee Gaeta will present on May 24, 2021, at 9:00 am ET. A live webcast will be available on the company's investor relations website, with an archived version accessible afterward. Establishment Labs specializes in women’s health, focusing on breast aesthetics and reconstruction, and markets silicone gel-filled Motiva Implants®, available in over 80 countries.
Establishment Labs Holdings (NASDAQ: ESTA) reported a record $30.3 million in sales for Q1 2021, up 24% from the previous year. The company raised its full-year revenue guidance to $118-$122 million, reflecting a 39% to 44% growth. First-quarter gross profit increased to $20.1 million (66.2% of revenue), while operating expenses decreased to $22.2 million. The net loss from operations improved to $2.1 million compared to $7.7 million in Q1 2020. The cash balance as of March 31, 2021, stood at $78 million, despite a $6.6 million decrease from the prior quarter.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced the completion of enrollment in its 100-patient Motiva Mia® case series in Costa Rica, approved by the Institutional Review Board. The study began in December 2020, following a previous case series in Asia. Led by 15 board-certified plastic surgeons from various countries, this prospective study aims to assess a minimally invasive breast enhancement procedure. The company has also submitted tools for CE marking, marking significant progress in its global regulatory strategy.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is set to announce its financial results for Q1 2021 on May 5, 2021, before market opens. A conference call will follow at 8:30 am ET. Establishment Labs specializes in women's health, particularly in breast aesthetics and reconstruction, offering innovative silicone gel-filled breast implants branded as Motiva Implants®. These implants are available in over 80 countries and produced in compliance with strict quality standards.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported record fourth quarter sales of $27.0 million, up 11% year-over-year, and provided 2021 guidance of $110 million to $112 million, reflecting a 30% to 32% growth. Operating expenses rose to $22.7 million, with a net loss from operations of $8.0 million. The company maintains a robust cash balance of $84.5 million. Key advancements include receiving CE mark for the new Motiva Ergonomix2 silicone implants and progress toward U.S. and Chinese market entry, with a total addressable market for Motiva Mia estimated at $4-5 billion.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has appointed Raj Denhoy as Head of Strategy and Investor Relations. Denhoy, formerly with Jefferies Group, brings over two decades of experience in the medical device industry. His role will involve defining corporate strategy and enhancing investor communication as the company aims for global leadership in breast aesthetics and reconstruction. Denhoy emphasized potential growth through the global rollout of Motiva implants and the upcoming MIA procedure, signaling optimism for sustained value creation.
Establishment Labs Holdings (NASDAQ: ESTA) is set to announce its financial results for Q4 2020 on March 10, 2021, before market open. A conference call will follow at 8:30 AM ET to discuss these results. The company specializes in women’s health, primarily in breast aesthetics, with its innovative Motiva Implants® and related technologies. Products are available in over 80 countries, adhering to strict regulatory standards. The company also initiated a clinical trial in the U.S. for Motiva Implants® after receiving FDA approval in March 2018.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that CEO Juan José Chacón-Quirós and CFO Renee Gaeta will attend the Cowen 41st Annual Healthcare Conference from March 1-4, 2021. They are scheduled to present on March 2, 2021, at 9:50 am ET. A live webcast of their presentation will be available on the company's investor relations website, with an archived version accessible post-event. Establishment Labs focuses on women’s health, primarily in breast aesthetics and reconstruction, with products like Motiva Implants® available in over 80 countries.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) hosted a virtual event on February 9, 2021, discussing its Motiva MIA system for minimally invasive breast augmentation. The MIA study shows reduced procedure time, lower post-operative pain, and quicker recovery compared to traditional methods. The company has expanded its clinical trials in Costa Rica and Thailand, aiming for regulatory approvals worldwide. Market research estimates a global market potential of $4-5 billion, indicating strong interest in the MIA system, with 50% of surveyed women willing to consider it over traditional surgery.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced CEO Juan José Chacón-Quirós and CFO Renee Gaeta will participate in the BTIG Virtual MedTech Conference from February 17-19, 2021. They are scheduled to present at 10:00 am ET on February 19. The conference offers a platform for discussions on the company's focus on women's health, particularly in breast aesthetics with their Motiva Implants®.
A live webcast and archived presentation will be accessible on their investor relations website.
FAQ
What is the current stock price of Establishment Labs Holdings (ESTA)?
What is the market cap of Establishment Labs Holdings (ESTA)?
What does Establishment Labs Holdings Inc. specialize in?
What is the flagship product of Establishment Labs?
In which regions does Establishment Labs operate?
How does Establishment Labs distribute its products?
What are the recent achievements of Establishment Labs?
What is the focus of Establishment Labs' ongoing projects?
How long has Establishment Labs been in the breast implant manufacturing industry?
What sets Motiva Implants® apart from other products in the market?
Is Establishment Labs a publicly traded company?
Where can I find the latest news about Establishment Labs Holdings Inc.?
